{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:46:46Z","timestamp":1791607606468,"version":"4.3.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271765"],"award-info":[{"award-number":["82271765"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773778"],"award-info":[{"award-number":["81773778"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Talent Project established by Chinese Pharmaceutical Association Hospital Pharmacy department","award":["CPA-Z05-ZC-2023-003"],"award-info":[{"award-number":["CPA-Z05-ZC-2023-003"]}]},{"name":"Beijing Hospitals Authority Youth Programme","award":["QML20230811"],"award-info":[{"award-number":["QML20230811"]}]},{"name":"Youth Programme of Xuanwu Hospital of Capital Medical University","award":["QNPY202418"],"award-info":[{"award-number":["QNPY202418"]}]},{"name":"Youth Program of Beijing Municipal TCM Science and Technology Development Fund","award":["BJZYQN-2025-21"],"award-info":[{"award-number":["BJZYQN-2025-21"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10120-026-01769-0","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T23:54:25Z","timestamp":1781740465000},"page":"972-986","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["CXCL12 upregulates PD-L1 expression and promotes M2 polarisation of tumour-associated macrophages to confer anti-PD-1 resistance in gastric cancer"],"prefix":"10.1007","volume":"29","author":[{"given":"Chao","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boya","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panjie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingnan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zizhao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianzhe","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"issue":"1","key":"1769_CR1","first-page":"47","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4(1):47\u201353.","journal-title":"J Natl Cancer Cent"},{"issue":"1","key":"1769_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-024-01578-x","volume":"17","author":"X Chong","year":"2024","unstructured":"Chong X, Madeti Y, Cai J, et al. Recent developments in immunotherapy for gastrointestinal tract cancers[J]. J Hematology & Oncol. 2024;17(1):65.","journal-title":"J Hematology & Oncol"},{"issue":"1","key":"1769_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","volume":"22","author":"GP Dunn","year":"2004","unstructured":"Dunn GP, Old LJ, Schreiber RD. The Three Es of Cancer Immunoediting[J]. Annu Rev Immunol. 2004;22(1):329\u201360.","journal-title":"Annu Rev Immunol"},{"issue":"10418","key":"1769_CR4","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","volume":"402","author":"YY Janjigian","year":"2023","unstructured":"Janjigian YY, Kawazoe A, Bai Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402(10418):2197\u2013208.","journal-title":"Lancet"},{"issue":"10294","key":"1769_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line Nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. The Lancet. 2021;398(10294):27\u201340.","journal-title":"The Lancet"},{"issue":"10","key":"1769_CR6","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","volume":"6","author":"K Shitara","year":"2020","unstructured":"Shitara K, Van Cutsem E, Bang Y, et al. Efficacy and safety of Pembrolizumab or Pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer. JAMA Oncol. 2020;6(10):1571.","journal-title":"JAMA Oncol"},{"issue":"3","key":"1769_CR7","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1200\/JCO.23.00971","volume":"42","author":"C Lee","year":"2024","unstructured":"Lee C, Kim HS, Jung M, et al. Open-label, multicenter, randomized, biomarker-integrated umbrella trial for second-line treatment of advanced gastric cancer: K-Umbrella Gastric Cancer Study. J Clin Oncol. 2024;42(3):348\u201357.","journal-title":"J Clin Oncol"},{"key":"1769_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100907","volume":"66","author":"K Pang","year":"2023","unstructured":"Pang K, Shi Z, Wei L, et al. Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 blockade. Drug Resist Updates. 2023;66:100907.","journal-title":"Drug Resist Updates"},{"key":"1769_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000398","author":"HM Kluger","year":"2020","unstructured":"Kluger HM, Tawbi HA, Ascierto ML, et al. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2019-000398.","journal-title":"J Immunother Cancer"},{"key":"1769_CR10","doi-asserted-by":"crossref","unstructured":"Wang F, Zhang X, Tang L, et al. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023.[J]. Cancer communications (London, England), 2024,44(1):127\u2013172.","DOI":"10.1002\/cac2.12516"},{"key":"1769_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-020-00212-5","volume":"8","author":"J Sun","year":"2020","unstructured":"Sun J, Zhang D, Wu S, et al. Resistance to PD-1\/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. Biomark Res. 2020;8:35.","journal-title":"Biomark Res"},{"key":"1769_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1285343","volume":"14","author":"K Liu","year":"2023","unstructured":"Liu K, Yuan S, Wang C, et al. Resistance to immune checkpoint inhibitors in gastric cancer. Front Pharmacol. 2023;14:1285343.","journal-title":"Front Pharmacol"},{"issue":"7","key":"1769_CR13","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.trecan.2024.03.008","volume":"10","author":"T Yasuda","year":"2024","unstructured":"Yasuda T, Wang YA. Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development. Trends Cancer. 2024;10(7):627\u201342.","journal-title":"Trends Cancer"},{"issue":"1","key":"1769_CR14","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12943-024-02176-8","volume":"23","author":"M Jin","year":"2024","unstructured":"Jin M, Fang J, Peng J, et al. PD-1\/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies. Mol Cancer. 2024;23(1):266.","journal-title":"Mol Cancer"},{"key":"1769_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-332901","author":"SH Lee","year":"2024","unstructured":"Lee SH, Lee D, Choi J, et al. Spatial dissection of tumour microenvironments in gastric cancers reveals the immunosuppressive crosstalk between CCL2+ fibroblasts and STAT3-activated macrophages. Gut. 2024. https:\/\/doi.org\/10.1136\/gutjnl-2024-332901.","journal-title":"Gut"},{"issue":"4","key":"1769_CR16","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707\u201323.","journal-title":"Cell"},{"issue":"1","key":"1769_CR17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-023-01725-x","volume":"22","author":"H Zhang","year":"2023","unstructured":"Zhang H, Liu L, Liu J, et al. Roles of tumor-associated macrophages in anti-PD-1\/PD-L1 immunotherapy for solid cancers. Mol Cancer. 2023;22(1):58.","journal-title":"Mol Cancer"},{"issue":"18","key":"1769_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202413019","volume":"12","author":"G Zhang","year":"2025","unstructured":"Zhang G, Zhang X, Pan W, et al. Dissecting the spatial and single-cell transcriptomic architecture of cancer stem cell niche driving tumor progression in gastric cancer. Adv Sci. 2025;12(18):e2413019.","journal-title":"Adv Sci"},{"issue":"5","key":"1769_CR19","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1158\/2159-8290.CD-23-0857","volume":"14","author":"M An","year":"2024","unstructured":"An M, Mehta A, Min BH, et al. Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer. Cancer Discov. 2024;14(5):766\u201385.","journal-title":"Cancer Discov"},{"issue":"11","key":"1769_CR20","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.7150\/ijbs.82317","volume":"19","author":"Y Yang","year":"2023","unstructured":"Yang Y, Li J, Lei W, et al. CXCL12-CXCR4\/CXCR7 axis in cancer: from mechanisms to clinical applications. Int J Biol Sci. 2023;19(11):3341\u201359.","journal-title":"Int J Biol Sci"},{"key":"1769_CR21","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.semcancer.2019.12.007","volume":"65","author":"SK Daniel","year":"2020","unstructured":"Daniel SK, Seo YD, Pillarisetty VG. The CXCL12-CXCR4\/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies. Semin Cancer Biol. 2020;65:176\u201388.","journal-title":"Semin Cancer Biol"},{"key":"1769_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105092","volume":"161","author":"C Huynh","year":"2020","unstructured":"Huynh C, Dingemanse J, Meyer Zu Schwabedissen HE, et al. Relevance of the CXCR4\/CXCR7-CXCL12 axis and its effect in pathophysiological conditions. Pharmacol Res. 2020;161:105092.","journal-title":"Pharmacol Res"},{"key":"1769_CR23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cytogfr.2023.10.003","volume":"75","author":"DP Anastasiadou","year":"2024","unstructured":"Anastasiadou DP, Quesnel A, Duran CL, et al. An emerging paradigm of CXCL12 involvement in the metastatic cascade. Cytokine Growth Factor Rev. 2024;75:12\u201330.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1","key":"1769_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29151-5","volume":"13","author":"J Li","year":"2022","unstructured":"Li J, Shu X, Xu J, et al. S100A9-CXCL12 activation in BRCA1-mutant breast cancer promotes an immunosuppressive microenvironment associated with resistance to immunotherapy. Nat Commun. 2022;13(1):1481.","journal-title":"Nat Commun"},{"issue":"1","key":"1769_CR25","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12943-021-01475-8","volume":"20","author":"D Chen","year":"2021","unstructured":"Chen D, Sheng H, Zhang D, et al. The circular RNA circDLG1 promotes gastric cancer progression and anti-PD-1 resistance through the regulation of CXCL12 by sponging miR-141\u20133p[J]. Mol Cancer. 2021;20(1):166.","journal-title":"Mol Cancer"},{"issue":"6222","key":"1769_CR26","doi-asserted-by":"publisher","DOI":"10.1126\/science.1258367","volume":"347","author":"HC Fan","year":"2015","unstructured":"Fan HC, Fu GK, Fodor SPA. Expression profiling. Combinatorial labeling of single cells for gene expression cytometry. Science (New York, NY). 2015;347(6222):1258367.","journal-title":"Science (New York, NY)"},{"issue":"5","key":"1769_CR27","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler A, Hoffman P, Smibert P, et al. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol. 2018;36(5):411\u201320.","journal-title":"Nat Biotechnol"},{"issue":"7","key":"1769_CR28","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart T, Butler A, Hoffman P, et al. Comprehensive integration of single-cell data. Cell. 2019;177(7):1888\u2013902.","journal-title":"Cell"},{"issue":"2","key":"1769_CR29","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","volume":"20","author":"D Aran","year":"2019","unstructured":"Aran D, Looney AP, Liu L, et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol. 2019;20(2):163\u201372.","journal-title":"Nat Immunol"},{"issue":"51","key":"1769_CR30","doi-asserted-by":"publisher","first-page":"21984","DOI":"10.1073\/pnas.0910040106","volume":"106","author":"B Lomenick","year":"2009","unstructured":"Lomenick B, Hao R, Jonai N, et al. Target identification using drug affinity responsive target stability (DARTS). Proceed National Acad Sci United States Am. 2009;106(51):21984\u20139.","journal-title":"Proceed National Acad Sci United States Am"},{"issue":"3","key":"1769_CR31","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/annonc\/mdv615","volume":"27","author":"J Chen","year":"2016","unstructured":"Chen J, Jiang CC, Jin L, et al. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol. 2016;27(3):409\u201316.","journal-title":"Ann Oncol"},{"issue":"5","key":"1769_CR32","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1002\/ijc.29519","volume":"138","author":"K Balamurugan","year":"2016","unstructured":"Balamurugan K. HIF-1 at the crossroads of hypoxia, inflammation, and cancer. Int J Cancer. 2016;138(5):1058\u201366.","journal-title":"Int J Cancer"},{"issue":"11","key":"1769_CR33","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.4251\/wjgo.v12.i11.1346","volume":"12","author":"L Yang","year":"2020","unstructured":"Yang L, Dong X, Xing X, et al. Efficacy and safety of anti-PD-1\/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: a meta-analysis. World J Gastrointestinal Oncol. 2020;12(11):1346\u201363.","journal-title":"World J Gastrointestinal Oncol"},{"issue":"3","key":"1769_CR34","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.4637","volume":"5","author":"N Zhuo","year":"2022","unstructured":"Zhuo N, Liu C, Zhang Q, et al. Characteristics and prognosis of acquired resistance to immune checkpoint inhibitors in gastrointestinal cancer. JAMA Netw Open. 2022;5(3):e224637.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"1769_CR35","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s10120-022-01359-w","volume":"26","author":"A Venkatasamy","year":"2023","unstructured":"Venkatasamy A, Guerin E, Reichardt W, et al. Morpho-functional analysis of patient-derived xenografts reveals differential impact of gastric cancer and chemotherapy on the tumor ecosystem, affecting immune check point, metabolism, and sarcopenia. Gastric Cancer\u202f: Official J Int Gastric Cancer Association the Japan Gastric Cancer Association. 2023;26(2):220\u201333.","journal-title":"Gastric Cancer : Official J Int Gastric Cancer Association the Japan Gastric Cancer Association"},{"issue":"1","key":"1769_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-1144-6","volume":"19","author":"D Ren","year":"2020","unstructured":"Ren D, Hua Y, Yu B, et al. Predictive biomarkers and mechanisms underlying resistance to PD1\/PD-L1 blockade cancer immunotherapy. Mol Cancer. 2020;19(1):19.","journal-title":"Mol Cancer"},{"issue":"11","key":"1769_CR37","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nri3088","volume":"11","author":"T Lawrence","year":"2011","unstructured":"Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol. 2011;11(11):750\u201361.","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"1769_CR38","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201910698","volume":"11","author":"H Wu","year":"2019","unstructured":"Wu H, Han Y, Rodriguez Sillke Y, et al. Lipid droplet-dependent fatty acid metabolism controls the immune suppressive phenotype of tumor-associated macrophages. EMBO Mol Med. 2019;11(11):e10698.","journal-title":"EMBO Mol Med"},{"issue":"8","key":"1769_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0069182","volume":"8","author":"S Wang","year":"2013","unstructured":"Wang S, Yu C, Hong J, et al. Radiation therapy-induced tumor invasiveness is associated with SDF-1-regulated macrophage mobilization and vasculogenesis. PLoS ONE. 2013;8(8):e69182.","journal-title":"PLoS ONE"},{"issue":"5","key":"1769_CR40","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","volume":"211","author":"MZ Noman","year":"2014","unstructured":"Noman MZ, Desantis G, Janji B, et al. PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211(5):781\u201390.","journal-title":"J Exp Med"},{"issue":"2","key":"1769_CR41","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.immuni.2019.01.006","volume":"50","author":"CS Pai","year":"2019","unstructured":"Pai CS, Huang JT, Lu X, et al. Clonal Deletion of Tumor-Specific T Cells by Interferon-\u03b3 Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. Immunity. 2019;50(2):477\u201392.","journal-title":"Immunity"},{"issue":"10427","key":"1769_CR42","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, Carlino MS, Khattak A, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet (London, England). 2024;403(10427):632\u201344.","journal-title":"Lancet (London, England)"},{"issue":"1","key":"1769_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01242-2","volume":"15","author":"M Wu","year":"2022","unstructured":"Wu M, Huang Q, Xie Y, et al. Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation. J Hematol Oncol. 2022;15(1):24.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1769_CR44","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41423-023-01112-y","volume":"21","author":"F Luo","year":"2024","unstructured":"Luo F, Li H, Ma W, et al. The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation. Cellular & Molecular Immunol. 2024;21(1):60\u201379.","journal-title":"Cellular & Molecular Immunol"},{"key":"1769_CR45","doi-asserted-by":"crossref","unstructured":"Cousin S, Gu\u00e9gan J, Shitara K, et al. Identification of microenvironment features associated with primary resistance to anti-PD-1\/PD-L1\u2009+\u2009antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomics.[Z]. 2024: 23, 197.","DOI":"10.1186\/s12943-024-02092-x"},{"issue":"2","key":"1769_CR46","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1158\/2326-6066.CIR-24-0324","volume":"13","author":"S Morita","year":"2025","unstructured":"Morita S, Lei P, Shigeta K, et al. Combination CXCR4 and PD-1 Blockade Enhances Intratumoral Dendritic Cell Activation and Immune Responses Against Hepatocellular Carcinoma. Cancer Immunol Res. 2025;13(2):162\u201370.","journal-title":"Cancer Immunol Res"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-026-01769-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-026-01769-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-026-01769-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:53:20Z","timestamp":1787896400000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-026-01769-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1769"],"URL":"https:\/\/doi.org\/10.1007\/s10120-026-01769-0","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"15 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no potential conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}